“These results clearly demonstrate that ResApp’s diagnostic tool outperforms experienced clinicians using stethoscopes and can match the results provided by an entire suite of expensive, time-consuming clinical tests,” said Dr Tony Keating, CEO and Managing Director of ResApp. “We are confident that ResApp’s accuracy will improve even further as we enrol more patients.”
2016 ---> the year of the RAPtor
Ann: Breakthrough Performance in Paediatric Clinical Study, page-7
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
